Genomic Signatures in Breast Cancer in a Real-world Setting: Experience in a Brazilian Northeastern Center

Overview

Journal Breast Dis

Publisher Sage Publications

Specialty Gynecology & Obstetrics

Date 2024 Jul 12

PMID 38995764

Authors

Sabas Carlos Vieira

Cristiane Amaral Dos Reis

Mariana Elvas Feitosa Holanda

Danilo Rafael da Silva Fontinele

Alessandro Igor Cavalcanti Leal

Fernanda Teresa de Lima

Affiliations

Soon will be listed here.

Abstract

Objective: We aim to evaluate the indication and use of genomic signatures in breast cancer patients and outcomes who in patients undergoing adjuvant chemotherapy or not.

Methods: This is a retrospective study of breast cancer patients managed in a private oncology clinic in Teresina, from November 2014 to February 2021. All patients with an indication of genomic signature were included. Clinical and pathological variables, use of genomic signatures, treatment and follow-up were obtained. The nomogram to predict Oncotype DX results (University of Tennessee Medical Center) was also calculated. Clinical risk calculation was based on MINDACT, using the modified version of Adjuvant Online. The genetic signatures performed were: the Oncotype, MammaPrint and EndoPredict.

Results: Fifty (50) female patients were included in the study. The mean age of the participants was 57.1 years. Among the patients receiving a genomic signature (26-52.0%), there was a change in treatment in 8 (30.7%) cases. Chemotherapy was indicated in four patients, It was contraindicated in another four patients. Treatment changed in 30.7% of the tested patients. Chemotherapy was indicated for those who would not receive it before. It was contraindicated in patients who would previously undergo chemotherapy.

References

Mariotto A, Jayasekerea J, Petkov V, Schechter C, Enewold L, Helzlsouer K . Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. J Natl Cancer Inst. 2019; 112(2):154-160. PMC: 7019096. DOI: 10.1093/jnci/djz068. View

Crolley V, Marashi H, Rawther S, Sirohi B, Parton M, Graham J . The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience. Breast Cancer Res Treat. 2020; 180(3):809-817. PMC: 7103011. DOI: 10.1007/s10549-020-05578-6. View

de Abreu F, Schwartz G, Wells W, Tsongalis G . Personalized therapy for breast cancer. Clin Genet. 2014; 86(1):62-7. DOI: 10.1111/cge.12381. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28(11):1829-34. DOI: 10.1200/JCO.2009.24.4798. View

Oliveira L, Megid T, Dornelles Rosa D, Magliano C, Assad D, Argolo D . Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. Ther Adv Med Oncol. 2023; 14:17588359221141760. PMC: 9806428. DOI: 10.1177/17588359221141760. View

Losk K, Freedman R, Laws A, Kantor O, Mittendorf E, Tan-Wasielewski Z . Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2020; 185(1):215-227. DOI: 10.1007/s10549-020-05931-9. View

Puppe J, Seifert T, Eichler C, Pilch H, Mallmann P, Malter W . Genomic Signatures in Luminal Breast Cancer. Breast Care (Basel). 2020; 15(4):355-365. PMC: 7490652. DOI: 10.1159/000509846. View

10.

Loncaster J, Armstrong A, Howell S, Wilson G, Welch R, Chittalia A . Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. Eur J Surg Oncol. 2017; 43(5):931-937. DOI: 10.1016/j.ejso.2016.12.010. View

11.

Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I . Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2009; 11(1):55-65. PMC: 3058239. DOI: 10.1016/S1470-2045(09)70314-6. View

12.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

13.

Enewold L, Geiger A, Zujewski J, Harlan L . Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy. Breast Cancer Res Treat. 2015; 151(1):149-56. DOI: 10.1007/s10549-015-3366-7. View

14.

Orucevic A, Bell J, King M, McNabb A, Heidel R . Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast. 2019; 46:116-125. DOI: 10.1016/j.breast.2019.05.006. View

15.

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015; 373(21):2005-14. PMC: 4701034. DOI: 10.1056/NEJMoa1510764. View

16.

Sabatier R, Goncalves A, Bertucci F . Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol. 2014; 91(3):223-33. DOI: 10.1016/j.critrevonc.2014.03.002. View

17.

Wishart G, Azzato E, Greenberg D, Rashbass J, Kearins O, Lawrence G . PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010; 12(1):R1. PMC: 2880419. DOI: 10.1186/bcr2464. View

18.

Mattar A, Fonseca G, Romao M, Shida J, de Oliveira V, Bastos M . Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in Brazil. JCO Glob Oncol. 2021; 7:1003-1011. PMC: 8457870. DOI: 10.1200/GO.20.00609. View